Intraperitoneal insulin infusion using implantable devices in insulin-dependent diabetic (IDDM) patients is promising since it improves diabetic control and decreases frequency of hypoglycaemia. However, preliminary data show a striking increase in plasma levels of anti-insulin antibodies with this therapy. In order to more precisely evaluate the immunogenicity and its consequences, anti-insulin antibody levels in 62 IDDM patients were assessed every 3 months during a 2-year period following pump implantation. At the same time, diabetes control was evaluated with HbA~c , mean blood glucose levels, standard deviation of the daily blood glucose levels and the frequency of low blood glucose (< 3.58 mmol/1). Factors involved in antibody formation such as age, gender, HLA typing, and complement C4 alleles were also studied. After implantation, anti-insulin antibody levels increased significantly from 3.14 % (range 0-26 %) to 8.34 % (0-49 %) after 1 year and remained elevated. Patients were divided into two groups: responders able to show at least one antiinsulin antibody titre higher than 15 % and non-responders whose titres were always lower than 6 %. None of the factors studied was shown to statistically influence the anti-insulin antibody titres. Non-respouders had significantly better metabolic results than the responders. Severe hypoglycaemic episodes decreased dramatically in both groups. Insulin requirements were comparable at time 0 and decreased initially in both groups. They remained low for the non-responders but returned to pre-implantation values for responders. Intraperitoneal insulin infusion led to a high immunogenetic response towards insulin in about half of the patients, leading to only moderately deleterious effects on metabolic control. Further studies are necessary to document other consequences (such as the role of circulating immune complexes). [Diabetologia (1995) que mainly due to the improvement in quality of life. The first results of efficacy studies are encouraging [3] since they demonstrate a drastic reduction in the incidence of severe hypoglycaemic episodes when compared to subcutaneous insulin administration [2, 4] . However, preliminary data from our group and from others have shown a striking increase in anti-insulin antibody levels (AIA) in plasma during longterm i.p. insulin infusion using implanted devices [5] [6] [7] [8] [9] . The aim of this study was to evaluate more precisely the immunogenicity of this new method of treatment, to define the different factors involved and to assess the eventual clinical and metabolic consequences of this immune reaction.
que mainly due to the improvement in quality of life. The first results of efficacy studies are encouraging [3] since they demonstrate a drastic reduction in the incidence of severe hypoglycaemic episodes when compared to subcutaneous insulin administration [2, 4] . However, preliminary data from our group and from others have shown a striking increase in anti-insulin antibody levels (AIA) in plasma during longterm i.p. insulin infusion using implanted devices [5] [6] [7] [8] [9] . The aim of this study was to evaluate more precisely the immunogenicity of this new method of treatment, to define the different factors involved and to assess the eventual clinical and metabolic consequences of this immune reaction. The intra-assay coefficient of variation was 7.9 % for an antibody level of 8.1%, 9 for 17.3 %, 7.6 for 37.9 %. The between assay coefficient of variation was 15.3 for 7.9 %, 16.3 for 21.3 % and 9.2 for 46.7 %.
Diabetes control was assessed by HbA~ measurements which
were performed using the DIAMAT HPLC System (BioRad, Hercules, Calif., USA) [11] , (normal values from 4.3 to 6.1%) and patients' capillary blood glucose measurements were recorded using a memory glucose meter such as the Glucometer M (Bayer-Ames, Miles, USA) or the Glucoscan One Touch II (LifeScan, Johnson and Johnson, Milpitas, Calif., USA).
Subjects and methods
Patients. Two groups of patients were studied. Group I included 62 patients who were treated with an implantable programmable insulin pump. They were all, C-peptide negative insulindependent diabetic (IDDM) patients with at least 1 year diabetes duration. All had been treated with human insulin at least 3 months before implantation. Exclusion criteria included major medical or psychiatric disorders and severe late diabetic complications such as advanced nephropathy or unstabilized proliferative retinopathy. Group II included 62 unselected IDDM patients treated subcutaneously with human insulin, these patients serving as a control population. At the time of implantation, Group I patients and Group II patients were similar regarding body mass index, age and diabetes duration as shown in Table 1 .
Devices and insulin.
Three different types of devices were used in this study; Infusaid Model 1000 (Shiley Infusaid, Norwood, Mass., USA), Minimed MIP 2001 (Minimed Technologies, Sylmar, Calif., USA) and Siemens Promedos ID3 (Siemens Elema, Solna, Sweden) [10] .
The insulin used in all three devices is the 21 PH human semi-synthetic, Genapol stabilized insulin (Hoechst A.G. Frankfurt, Germany); a concentration of 400 U/ml for the MIP and 100 U/ml for the ID3 and the Infusaid 1000. The Genapol (polyethylenepolypropilene glycol) at a concentration of 10 ~g/ml acts as a surfactant avoiding the deformation of insulin molecules which may lead to insulin degradation (loss of biological activity and aggregates formation).
Methods

Immunogenicity of i.p. insulin infusion was assessed as follows:
Serum was tested for insulin antibodies using the Biomerieux (Lyon, France) radiobinding assay. The determination is performed in two steps according to the manufacturer's protocol. Serum samples (50 ~tl) were incubated for 24 h at 4~ with 200 ~1 of 112s porcine insulin in albumin phosphate buffer.
Following incubation, 30 ~tl of the mixture was incubated with 50 ~1 of normal human serum, 100 ~1 of human total antiIgG serum and 3 ml of 24 % polyethyleneglycol solution. The precipitate was centrifuged at 2000 g for 20 min at 4 ~ The supranatant was decanted and the pellets were assessed for radioactivity in a gamma-counter. The results are expressed as the percentage of bound counts (100 x bound counts / total input counts). The non-specific binding measured with a normal serum was subtracted from each sample result. Presence of AIA in a serum was established when the binding percentage was higher than 2 %.
Genetic background of the patients was assessed by HLA determination. Class II typing was performed on B lymphocytes isolated with magnetic immunobeads according to the method of Vartdal et al. [12] . The C4 complement ,factor polymorphism was assessed using an electrophoretic technique on the plasma samples previously treated with either neuraminidase alone or carboxypeptidase and neuraminidase.
Insulin requirements were calculated using the volume of insulin actually infused by the pump, corrected by the number of days between two refills.
Study design and protocoL All the patients were initially selected according to a feasibility and safety protocol. The protocol was approved by the local ethical committee. The pumps were implanted under general anaesthetic, in the left lower quadrant of the abdomen, and sutured to the fascia. The catheter was inserted blindly into the peritoneal cavity. Patients returned to the clinic at least every 3 months, for a refill or if any problems occurred.
A memory glucose meter was given to each patient about I month prior to implantation. They were told to perform at least four capillary measurements per day and measure postprandial blood glucose levels regularly; these data were entered in the memory as M1 (preprandial) or M2 (postprandial) in order to perform statistical analysis. The Glucofacts Data Management System (Ames) enables the calculation, for i month, of mean blood glucose levels, of the mean 24-h blood glucose standard deviations [5] which is a parameter used to evaluate blood glucose excursions and of the number of times blood glucose falls below 3.58 retool/1.
Biomerieux AIA levels were determined for Group I and Group II patients. In Group I patients, AIA were assessed during the 4 weeks preceding the implantation and then every 3 months. HbAlc levels were measured at the time of implantation and then every 3 months at each AIA assessment. Daily insulin requirements were determined at each refill; therefore, the first evaluation was done 1 or 2 months after implantation, depending on the type of device.
Three types of patients were characterized at the end of the study by assessing the division of the population by AIA levels calculated from 12 to 24 months (Fig. 1) .
Responders (n = 25) whose AIA titres reached at least once a level of 15 %, (these patients were considered to have a high antigenic reaction against the insulin used).
Non-responders (n = 24) whose AIA titres were always lower than 6 % during the entire study.
Thirteen patients had intermediate values.
Statistical analysis
All data are presented as means + SEM unless otherwise stated. All AIA data were transformed to logarithms (after the addition of one to each number) for each antibody level in order to normalize the distribution of values before statistical evaluations [5] . All data are expressed as percent and are derived from the logarithms. The mean of 12 to 24 months were compared to the pre-implantation levels using the paired Student's t-test of the log-transformed data since it is not relevant to repeat the tests for each period of time. Chi-square was used for all frequency comparisons. A linear regression was used to evaluate the relationship between the pre-implantation AIA levels and the peak reached in the post-implantation period. Statistical significance was considered for p-values less than 0.05. . Of the patients 6.5 % (n = 4) in Group I prior to implantation and 1.6 % (n : 1) in Group II had an AIA level higher than 15 %; at the same time 82 % (n = 51) of patients in Group I and 84 % (n = 52) in Group II had AIA levels lower than 6 %.
Results
16]
Evolution of AIA levels during i. p. insulin infusion in
Group L After implantation, AIA levels in Group I increased significantly from 3.40% (0-26%) at month 0 to 8.34 % (0-49 %) (mean of month 12 to month 24) (Fig. 2) . The percentage of patients whose AIA was equal or higher than 15 % increased from 6.5% (n=4) at months0 to 40% (n=29) after I year, and remained stable thereafter. Mean AIA titres in the responder group increased after 3 months compared to the pre-implantation period and remained elevated thereafter.
Factors involved in AIA formation
Age: Mean age at the time of implantation was comparable for responders (37.84 + 2.04 years) and nonresponders(35.29 + 1.80 years). Of the six patients over 50 years old, four (66 %) were responders, one (16 %) was a non-responder. Among the nine patients younger than 30 years, four (44%) were responders and four (44%) were non-responders (NS).
Gender: There were 11 males (46 %) and 13 females (54%) in the non-responder group compared to 13 males (52%) and 12females (48%) in the responder group (NS). Diabetes duration: Mean diabetes duration was similar among responders (18.7 + 1.6 years) and non-responders: (15.4+_ 1.5 years); for the four patients with diabetes duration of less than 5 years, one was a responder, three were non-responders, for the nine patients with diabetes duration longer than 25 years, four were in the non-responder and three were in the responder group (NS).
Insulin therapy prior to implantation. In Group I, only one patient had less than 2 years of insulin treatment, he was treated with multiple injections (MI); his preimplantation AIA level was 0 % and he became a responder. Five control subjects were treated for less than 2 years; they were treated with MI, their AIA levels were respectively: 0, 0, 0, 0 and 3.5 %. Nineteen patients were treated with regular insulin only (continuous subcutaneous insulin infusion (CSII)) and 43 patients used regular and intermediate insulin. AIA levels prior to implantation were 4.81% (0-18 %) for continuous subcutaneous insulin infusion (CSII) patients and 2.77% (0-18.5 %) for M I patients (NS). All control subjects except one whose AIA titre was 0 %, were M I. All our CSII patients had been on porcine insulin and changed to human insulin 6 to 3 months prior to implant. One year after implant their AIA levels were slightly higher than the M I patients: 10.43% (0-49 %) vs 7.30 % (0-42 %) (NS).
Genetic background. HLA typing for all patients and complement factor nul alleles for C4 for the first 39 subjects are shown in Table 2 .
Insulin concentration. AIA levels increased in the same way for the two insulin concentrations used in the pumps from 3.39 % (U 100) vs 3.40 % (U 400) to 9.43 % (U 100) vs 7.81% (U 400) after 3 months. They remained comparable until the end of the study (9.35 % U 100 vs 8.93 % U 400). There was no difference in the ratio non-responder/responder in the group of patients treated with U 400 (36 % nonresponder -38 % responder) or U 100 (45 % nonresponder -45 % responder).
AIA level before implantation. There is a significant correlation (r = 0.63 p < 0.0005) between the AIA levels prior to implantation and the maximum peak reached during the study, a higher level of AIA before implantation was also found in the responder group (p < 0.001). Calculated for a mean of 1.4 years per patient compared to pre-implantation (calculated during 2 years for each patient) in non-AIA forming group (non-responders) and AIA forming group (responders). Expressed as numbers per 100 patient years matically decreased during pump therapy for all patients as shown in Table 3 . No statistically significant difference in insulin requirements was found between the responder and non-responder groups during the entire course of the study. Insulin requirements decreased significantly for non-responder patients (p < 0.01). In the responder group, after a significant decrease during the first 9 months (p < 0.01), insulin requirements increased again to pre-implantation levels and then remained stable until the end of the study (Fig. 8) .
Consequences of metabolic control
Impact on catheter function. Frequency of catheter obstruction was similar in the two groups, 20% (n = 4) in the non-responder group and 16 % (n = 3) in the responder group, the small number of catheter obstructions in the two groups does not allow any statistically significant difference (r = 3).
Clinical consequences: two case reports. The clinical relevance of very high AIA titres remains to be assessed, since in some cases it may lead to interruption of therapy. Two of our patients, one male and one female (both HLA DR4) whose AIA titres were very high, up to 40 %, suffered from clinical symptoms similar to the "insulin autoimmune syndrome" [14] such as a dramatic nocturnal fall in blood glucose (5.5 to 11 mmol/1 despite a complete pump stop for 6 to 8 h) and a very severe insulin resistance during the day.
One of the patients often had massive ketonuria during the day with a basal rate of 3 U/h and blood glucose around 11 mmol/1. HbAI~ increased from 6.9 % at the beginning of the symptoms (AIA of 20 %) to 10.5 % at the end of pump therapy (AIA of 25.7 %). Free insulin levels increased at night time from an average of 15 ~U/ml during the day to 77 pU/ml at 24.00 hours and 39 ~U/ml at 04.00 hours. At the same time total insulin levels were over 192 000 ~U/ml. A laparoscopy was performed, the catheter was not encapsulated and the peritoneum was free of adhesions, the pump was changed and thus the insulin concentration changed from U 100 to U 400. Metabolic results were slightly improved for about i month, in particular the insulin resistance symptoms (disappearance of ketonuria), then all the symptoms reappeared. The patient was changed from i.p. infusion to a porcine insulin subcutaneous infusion; the symptoms remained stable for about 9 months and are now improving with a stabilization of nighttime blood glucose levels and a decrease in daytime insulin requirements. It is very difficult to definitely link these types of symptoms to a high AIA level, even though the patient's AIA levels tended to decrease slightly after changing to porcine subcutaneous therapy, AIA titres were at 28.7% when i.p. insulin was resumed, 30 % after 4 months of subcutaneous therapy and 17.8 % at the improvement stage. To detect an eventual difference between the types of AIA observed in these patients compared to the others, a Scatchard technique [15] was performed on four other patients presenting very high AIA levels (over 30 %) and severe, light or no clinical symptoms. There was no striking difference between the AIA constant of association or the number of high affinity sites.
Discussion
Our data confirm the positive effect of i.p. insulin infusion on metabolic control and particularly on diabetes stability, with a drastic reduction of severe hypoglycaemic episodes associated with an improvement of diabetes control [2] ; this was a positive aspect considering the results of the DCCT study [13[ . In our study the frequency of severe hypoglycaemia decreased in both groups (non-responder and responder) in the same way, showing that high AIA levels do not seem to increase the risk of severe hypoglycaemic episodes. Even if the pre-implantation data are retrospective, based on the patients, files and questionnaires from the 2 years prior to implant, the post-implantation data are prospective and the huge discrepancy between the frequency of events remains interesting and close to other published results [2] . Our data show that i.p. insulin leads to a high immunogenic response to insulin and this has been confirmed by others [5, 6, 8, 9] . Concerning their immune response towards insulin, our patients behave as normal diabetic patients, since their AIA levels prior to implantation were comparable to the AIA levels of the unselected IDDM patients seen in our clinic at the same time. Therefore, the increase in AIA levels observed in our study is probably specific to the mode of therapy.
AIA are very hard to characterize and to quantify, different assays may assess different types of antibodies whose properties and functions are not well understood. Differences may exist between the meth-N. Jeandidier et al.: Immunogenicity of peritoneal insulin ods used and between assays. No "gold standard" method is yet available. Radioimmunoassay dosages measure high affinity antibodies, and ELISA assay measures more specifically medium to low affinity AIA [16] . This adds to the difficulty of comparing titres between different studies.
AIA may fluctuate over time in a given patient as in a classic immune response with first, the formation of anti-insulin IgG followed by anti-IgG antibodies [17] . These fluctuations should be considered since most of the previous studies report only one or two titre values during the follow-up.
To minimize these difficulties, we evaluated the potential of each patient to achieve a high immune response. Therefore, we decided to look at the population AIA titres repartition once the immune response was achieved (after 12 months). Mean AIA levels in the non-responder group remain in the range considered as negative for the assay (n < 2 %): 0.53 % prior to implantation, 0.77 % after 24 months,
In order not to characterize our patients wrongly (classify a responder as a non-responder) we studied the AIA titres every 3 months and we checked that no new patient reached an AIA titre of 15 % after 18 months. Our data clearly show that only half of the patients had a significant increase in AIA titres; thus, there must be other factors involved.
Different factors described in the literature as being involved in AIA formation were studied. Our preliminary data [6] and those from other authors [18, 19] have found some genetic factors (HLA DR3 or complement factor allele C4AQ0) to be related to low AIA levels. This is not confirmed here, where none of the genetic factors seem to statistically influence the AIA titres, despite a tendency for the DR4 population to be part of the responder group. The small number of patients in each subgroup may be the cause of the absence of statistical significance. Older subjects seem more likely to become responders, as would be expected [20] . The other factors studied, i.e. diabetes duration and gender, do not seem to influence AIA formation.
Regular insulin is usually less immunogenetic than intermediate insulin, but our CSII patients had recently been treated with porcine insulin which may explain the slightly elevated AIA titres. Most of our patients had been insulin treated for a long time. Among the few recently treated, the very low AIA titres do not confirm the hypothesis of a high rise in AIA titres at the beginning of any subcutaneous human insulin therapy.
The AIA value of patients prior to implantation is related to the evolution of AIA levels, but is not predictive since 25 % of the patients with an AIA titre of 0 % prior to implantation became responders.
The route of insulin administration may influence the immunogenicity of insulin since some authors have described a sustained decrease in AIA titres after 6 and 12 months of intravenous insulin therapy using implantable devices [21] in non-insulin-dependent diabetic patients. A particular immunogenicity may be related to the peritoneal route since mice produce higher quantities of AIA in their serum after an i.p. insulin injection than after a subcutaneous injection [22] . Peritoneal B lymphocytes have also been described in mice as Ly 1 B lymphocytes, which are very sensitive and more reactive to immune stimulation than other classes of lymphocytes found in other tissues [23] .
The insulin used in this study is a semi-synthetic human purified insulin and thus should show very little immunogenicity [24] [25] [26] . In this study neither the difference in insulin concentration nor the type of device used had any consequence in the evolution of AIA titres.
The Genapol used to stabilize the insulin may be one of the factors to consider, by acting as a carrier. Some studies concerning this insulin [27] have reported that 5 % of the insulin infused could be modified before reaching the body. The chemical nature of the derivative is not yet known but possesses full biological potency. The fact that it does not lead to increased AIA titres in pigs compared to standard human insulin does not exclude a role for this denatured product in our observations. It has been reported that 95 % of native insulin is found in the residual insulin collected from the pump reservoir during each refill, a small amount consists of desamidoinsulin (HPLC) which does not seem to be particularly antigenic in rabbits but may be immunogenetic in humans [28] . We found no data in the literature concerning the eventual immunogenicity of the high molecular weight component found by analysing the residual insulin by size exclusion chromatography [29] . Insulin aggregates have been shown to induce specific antibodies [30] and may be involved in the immune reaction observed.
As already reported, AIA do influence metabolic control [31] [32] [33] [34] [35] particularly postprandial blood glucose. Some authors [9] found no direct correlation between the AIA levels and glycaemic control, nor did we. That might be explained by the high number of other parameters involved in the diabetic control at a given time (anxiety, diet, transient illness, technical problems). These parameters might have a greater influence on metabolic control, the influence of AIA titres remaining moderate.
Insulin requirements decreased at first in both responder and non-responder groups, due perhaps to improvement in diabetic control, and then increased again in the responder group after 9 months, closely following the AIA titres evolution. Nevertheless, insulin requirements remained comparable in both groups during the entire study.
Some "morning lows" have also been described [5] with the observation of clinical symptoms as soon as 583 the AIA titres are over 20 ~xU/ml. In our study clinical symptoms did not strictly correlate with the AIA titres and remained the same despite the titres fluctuations, four patients reached the same or higher levels of AIA (40 %) without any clinical symptoms. Since the RIA technique is known to select high avidity AIA, we could have missed some low or medium affinity AIA which could well be involved in these "morning lows", the low or medium affinity sites being linked more directly to the insulin bioavailability [36] .
The i.p. insulin infusion by means of implantable pumps significantly improves diabetic control and stability, with a dramatic decrease in severe hypoglycaemic episodes. Our data clearly demonstrate that this mode of therapy is immunogenetic, but that the elevation of AIA titres affects only half of the treated patients and has moderately deleterious effects on metabolic control and diabetic stability. A possible implication in rare cases of severely destabilized diabetes is suggested. Further studies are needed in order to isolate the factors and causes involved in these very rare clinical symptoms, in order to characterize these types of patients as "at-risk patients" who should not be given implants or the peritoneal route should be avoided as long as no simple therapy is found. Sulphated insulin has been tried in a few cases of insulin resistance but does not seem to be very efficient [37] , and steroids are not easy to use in diabetic patients. Recent studies have shown that different IgG sub-classes are triggered during insulin therapy in man [38] ; since the function of these subclasses is different it would be interesting to compare these different fractions in the patients suffering from the "morning low syndrome" and in other patients with high antibody levels and no symptoms.
